OGI stock steadies as Sanity lifts revenue share

Published on 09/02/2026 at 07:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

OGI stock is holding near $1.21 as Organigram Global Inc. pushes Sanity deeper into the revenue mix, with the German unit contributing C$40 million in the latest quarter and more than 35 percent of net revenue.

OGI, CA68620P1018, Illustration mit AI erstellt.

OGI stock of Organigram Global Inc. (CA68620P1018) is trading near $1.21, while Sanity added C$40 million in net revenue in the latest quarter and more than 35 percent of consolidated sales. As the filing summary showed, that German medical cannabis unit was also accretive to adjusted EBITDA.

Sanity drives the mix

The latest quarterly picture is dominated by Sanity: C$40 million in net revenue, over 35 percent of the total, and a positive contribution to adjusted EBITDA. The same disclosure places the amended earnout at C$20 million in cash plus about EUR 76 million in shares, with payment due between April 1, 2027 and May 1, 2027.

That structure matters because it turns Sanity from a simple growth asset into a quantifiable earnings lever. Organigram Global also reported a market capitalization of C$246,517,467 in the filing context, which puts the earnout against a clearly defined base.

Consensus points higher

Current consensus cited in the market data points to fiscal 2026 revenue of $252.28 million, up 34.33 percent year over year, with EPS expected at $0.58. For fiscal 2027 and fiscal 2028, the same set of estimates rises to $330.41 million and $350.98 million, showing that the growth case is not built on one quarter alone.

The quarter itself also provides a second comparison: first-quarter fiscal 2026 revenue was $63.54 million, with earnings of $19.97 million and a profit margin of 31.43 percent. That gives investors a concrete bridge between the latest reported quarter and the forward numbers now circulating in the market.

Go deeper

Sanity and the next revenue step

The German unit now carries more than a third of quarterly revenue, so the integration outcome is central to Organigram Global's next reporting step.

Organigram Global Inc. topic page Investor Relations

Product mix matters

Organigram's cannabis portfolio spans dried flower, pre-rolls, oils and medical-grade formulations, with Sanity extending the company into German medical cannabis. The operational point is simple: a broader product base now feeds the same consolidated quarter.

Price near $1.20

As of September 1, 2026, OGI stock traded at $1.21, down 0.82 percent on the day. The gap between that price and the C$246,517,467 market-cap context shows how much of the market still treats the story as a small-cap execution test.